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Leishmania infection consists in two sequential events, the hostcell colonization followed by the proliferation/dissemination of the
parasite.Inthisreview,wediscusstheimportanceoftwodistinctsetsofmolecules,thesecretedand/orsurfaceandthenonsecreted
antigens. The importance of the immune response against secreted and surface antigens is noted in the establishment of the infec-
tion and we dissect the contribution of the nonsecreted antigens in the immunopathology associated with leishmaniasis, showing
the importance of these panantigens during the course of the infection. As a further example of proteins belonging to these two
diﬀerent groups, we include several laboratorial observations on Leishmania Sir2 and LicTXNPx as excreted/secreted proteins and
LmS3arp and LimTXNPx as nonsecreted/panantigens. The role of these two groups of antigens in the immune response observed
during the infection is discussed.
Copyright © 2007 Nuno Santar´ em et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Leishmaniasis are parasitic diseases, caused by protozoan
parasites of the Leishmania genus, associated with signiﬁcant
morbidity and mortality in tropical and subtropical regions
andintheMediterraneanbasin.Thediseasehasawiderange
of clinical manifestations that depend not only on the infect-
ing Leishmania species but also on the immune status of the
host [1]. The most extensively studied leishmanial disease is
thecutaneousformcausedbyL.major orL.tropicaintheold
world and L. braziliensis in the new world. It usually appears
as a skin ulcer or dermal granuloma, which may take up to
s e v e r a lm o n t h so ry e a r st oh e a l[ 2]. With L. braziliensis, the
infection may also spread to other cutaneous sites, like mu-
cosal membranes giving origin to the mucocutaneous form
of the disease. The most serious form of the disease is the vis-
ceral one that, if untreated, gives rise to a high mortality rate.
It is characterized by fever, cachexia, hepatosplenomegaly,
and hypergamaglobulinemia and is caused by members of
the L. donovani complex (L. donovani in the old world, L. in-
fantum in the Mediterranean basin and L. infantum chagasi
in the New World) [3].
Leishmania is a digenetic protozoan that is transmitted
to the mammalian host by sandﬂies of the genus Phleboto-
mus in the old world and Lutzomyia in the new world. In the
alimentary tract of the insect vector, the parasite exists ex-
tracellularly as a ﬂagellated motile form, the promastigote.
During the insect blood meal, the infectious developmental
form, metacyclic promastigotes, is injected into the dermis
and phagocyted by resident macrophages within which the
parasite diﬀerentiates into the nonmotile amastigote form
and multiplies. Moreover, other cells such as ﬁbroblasts and
dendritic cells may also harbour parasites [4]. The cycle is
completed when the sandﬂy takes another blood meal recov-
ering free amastigotes or infected macrophages.
During an infection, the parasites have a remarkable
adaptative capacity as they are able to survive inside phago-
cytic cells. These cells are responsible for the microbicidal
and antigen-presenting functions however they serve as a
safe habitat for the parasite. The existence of inbred mice,
which are either susceptible (Balb/c) or resistant to infection
(C57BL/6, CBA, C3H.HeJ) has helped to elucidate the pro-
tective or nonprotective role of cytokine and T-helper cell
subsets and also the role of diﬀerent leishmanial antigens
in the immune evasion mechanism. Thus, it became gen-
erally accepted that resistance against leishmaniasis is asso-
ciated with the production of IL-12 by antigen presenting
cells (APC) macrophages and dendritic cells, leading to the2 Journal of Biomedicine and Biotechnology
diﬀerentiation and proliferation of the Th1-subset of CD4+
T-cellsproducersofIFN-γ.Thiswillultimatelyleadtotheac-
tivation of parasite-infected macrophages that, through the
induction of eﬀector molecules as nitrogen and oxygen re-
active species, will kill the intracellular parasites [5]. In con-
trast, failure to control the infection has been associated with
the production of anti-inﬂammatory cytokines as IL-4, IL-
10, IL-13 and TGF-β [6]. Given the ancient evolutionary di-
vergence in Leishmania species, it is not surprising that the
control of the diﬀerent Leishmania driven diseases is related
to diﬀerent immunological properties. Hence, while in cuta-
neous leishmaniasis, IL-4 has been implicated in disease pro-
gression, in visceral leishmaniasis its importance has been
ruled out [7]. In the latter, IL-10 has been shown to be
the major immunosuppressive cytokine along with TGF-β.
Overall, it suggests that it is the overshadowing of the Th2
response by a Th1 cell associated response that leads to the
control of the infection [8]. Moreover, the real contribution
of the humoral response is still under debate, however stud-
ies in diﬀerent intracellular pathogens have shown that an-
tibodies can also have a function in restricting the infection
when the parasite is exposed to the extracellular milieu [9].
Consequently, in leishmaniasis, the induction of speciﬁc hu-
moral responses to parasite antigens would, theoretically, be
able to neutralize the parasite whether as free promastigotes,
after the inoculum, or as amastigotes, when released from
the infected macrophages, contributing to develop a protec-
tive response [10]. However, until now, no eﬀective vaccine
against human leishmaniasis is available for clinical use [3].
Leishmania parasites inside their hosts do not behave
inertly. Rather, the virulence related to their pathology seems
to be linked to an induced lack of immune response control.
The parasite actively secretes proteases and other molecules
that aﬀect host immune system (cells and cytokines) facil-
itating the infection process. In addition, the parasite pos-
sesses intracellular nonsecreted antigens, members of con-
served protein families, which are believed to contribute
to the chronic immunopathology, observed in leishmania-
sis. Here, we review these two groups of relevant parasite
molecules, illustrated with laboratory observations of pro-
teins belonging to the secreted and nonsecreted groups of
antigens. Finally, we discuss their diﬀerential role in Leish-
mania infection and persistence as well in the development
of a protective immune response.
1.1. Theimportanceofthesecretedversus
nonsecretedantigens
Leishmania virulence has been explained using two diﬀerent
groupsofparasitemolecules,thesecretedandsurfaceandthe
intracellular molecules [11]. This model proposes that the
secreted and surface molecules will be mostly important for
the establishment of infection, protecting the parasite from
the early action of the host immune system, acting as inva-
sive/evasive determinants. According to this model, the in-
tracellular molecules will be ultimately responsible for the
disease phenotype [11].
1.2. Surfaceandsecretedmolecules
The secreted proteins have distinct functions during Leish-
mania infection. First, they play a role in the establishment
of the infection [12] in conjunction with important elements
existentinthesalivaofthesandﬂyvector[13,14].Inasecond
phase, they contribute to the maintenance of the infection
by interfering with the macrophagic microbicidal functions,
cytokine production, antigen presentation, and eﬀector cells
activation. This is achieved by repression of gene expression,
post-translationproteinmodiﬁcationordegradation,andby
activation of suppressive pathways and molecules [15]. This
macrophagic anergy enables the continuous multiplication
of the amastigote form. The bulk of the knowledge on sur-
f a c ea n ds e c r e t e dm o l e c u l e so fLeishmania i sf o c u s e do nl y -
pophosphoglycan (LPG), on the promastigote surface pro-
tease named glycoprotein 63 (gp63), glycosylinositol phos-
pholipids (GIPLs), cysteine peptidases and on a few oth-
ers like β-mercaptoethanol activated proteases, acid phos-
phatases and chitinases. The importance of some of these
molecules in the establishment of the infection is well doc-
umented [15, 16], but the real contribution of the secreted
molecules remains elusive due to the diﬃculty of the intra-
macrophagic studies.
After entrance into a susceptible mammalian host, the
Leishmania promastigotes are targeted by the host immune
system.Serumcomponents,likethecomplementsystemrep-
resent the ﬁrst challenge following entrance into the blood-
stream. Procyclic promastigotes are highly susceptible to
complement action, unlike the metacyclic that can avoid
complement mediated lysis [17]. This remarkable diﬀerence
ismostlyduetothesurfacemoleculeinLeishmania,theLPG.
Composed mainly of repetitive units of a disaccharide and
a phosphate, LPG is linked to the membrane by a glyco-
sylphosphatidylinositol anchor [18]. The LPG is longer in
metacyclic promastigotes preventing the attachment of C5b-
C9 subunits of the complement complex avoiding its lytic
action [17]. The relevance of LPG is not limited to com-
plement resistance. Its importance is stated by several stud-
ies using either puriﬁed LPG or mutant strains. The LPG
is implicated in several processes including the binding to
the epithelial cells of the sandﬂy midgut [19], receptor me-
diated phagocytosis of macrophages through the CR3/CR1
ligand or the manose-fucose receptor (in conjunction with
gp63) [20, 21], toll-like receptor 2 signalling [22], stimula-
tionofNKcells[23],inhibitionofphagosome-endosomefu-
sion [24–26], and inhibition of phagosome-derived superox-
ide [27]. Several attempts to use LPG to confer protection
were unproductive [28, 29]. Constitutively shed by several
Leishmania species, the LPG is the paradigm molecule re-
ferred to as evasive and invasive. After the initial steps of
infection, LPG is downregulated being almost absent from
amastigotes [30].
Another molecule implicated in the invasive and eva-
sive mechanisms is gp63. This protein is the most abun-
dant in the parasite surface, although 10 fold less abundant
than LPG [30]. In the promastigote form, gp63 is in the
surface of the parasite under the LPG coat and is involvedNuno Santar´ em et al. 3
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Figure 1: The LicTXNPx and LiTXN1 are excreted/secreted pro-
teins. Autoradiography of [35S] methionine labelled L. infantum
promastigotes lysate (PL) and excreted/secreted antigens (ES), af-
ter 3 hours of incubation experiments, immunoprecipitated in the
presence of immune anti-LicTXNPx or anti-LiTXN1 sera or with a
preimmune serum.
in L. donovani promastigote multiplication [31]. Like LPG,
gp63 was shown to be implicated in complement resistance,
in L. major and L. amazonensis, by mediating the intercon-
vertion of C3b to C3bi [32]. This interconvertion favours
the internalization via CR3 avoiding the oxidative burst. The
binding of gp63 to ﬁbronectin receptors favours the parasite
uptake into the macrophage [33]. Furthermore, gp63 is an
endopeptidase with the potential to degrade immunoglobu-
lins, complement factors, and lysosomal proteins [34]. The
optimal proteolitic activity of gp63 is at pH 4 that may indi-
cate some active proteolitic function in the amastigote stage
[34, 35]. Despite this, gp63 expression is downregulated in
amastigotes [36]. In spite of being a virulence factor in most
Leishmania species, immunization trials with gp63 were un-
able to protect mice from infectious challenge [37]. More-
over, gp63 mutation in L. major did not impair in vitro in-
tramacrophagic survival [38]. So the importance of gp63 in
the course of the infection remains elusive. The GIPLs are
molecules 10 times more abundant than LPG on the para-
site surface, although like gp63 they are physically under the
LPG coat [39]. The GIPLs were described in L. major as hav-
ing a protective role at the parasite surface by modulating the
expression of nitric oxide synthetase in murine macrophages
[40, 41]. Another interesting group of proteins are the cys-
teine proteases. In L. mexicana, this family of proteins seems
to be associated with disease progression [42]. Cysteine pro-
tease activity can be found at the parasite surface or inside
the macrophage endoplasmatic reticulum, probably associ-
ated with proteases released in the phagolysosome by Leish-
mania. The inhibition of major histocompatibility complex
class II molecules in macrophages seems to involve, in L.
amazonensis, the direct sequestering of these molecules fol-
lowing cysteine-peptidase-dependent degradation [43, 44].
Also, cysteine peptidase activity was demonstrated in L. mex-
icana to induce IL-12 repression and degradation of NF-kB
[45]. It is still worthy to mention some other secreted pro-
teinsdescribedasvirulencefactors,liketheL.mexicanachiti-
nase [46] and the L. donovani acid phosphatases [47–50]. An
in depth study of the Leishmania secretome is missing. The
most remarkable eﬀort was done by Chenik and colleagues
t h a tw e r ea b l et os c r e e n3 3d i ﬀerent proteins using an L. ma-
jor cDNA library and a rabbit immune sera raised against the
secreted proteins [51]. Nine of them were already described
as excreted/secreted proteins in Leishmania or other species,
11 corresponded to known proteins but not characterized as
secreted and the other 13 were completely new and unchar-
acterized proteins [51]. This shows how little is known about
theLeishmaniasecretomesinceonlyafewproteinsareexten-
sively characterized [52–56]. It is already known that total L.
major secreted molecules, described as highly immunogenic
[54, 57–59], can confer protection from infectious challenge
[57, 59]. So it is obvious that somewhere among the Leish-
mania secreted proteins exist future candidates for vaccine
design and drug targets. Nonetheless, one of the problems in
vaccine design using surface or secreted/excreted proteins is
the fact that these proteins are naturally exposed to the im-
munesystem.Changetalsuggestthatthesesecreted/excreted
proteins were evolutionarily selected becoming immunolog-
ically “silent” [60]. This fact implies that secreted proteins
that have a speciﬁc function in the establishment of the in-
fection will be “silent,” allowing them to perform their vital
functions unchecked by the host immune system [11, 12].
This will be more signiﬁcant for the proteins involved in the
ﬁrst steps of infection, while the parasite is still exposed to
the extracellular environment. As an example of this fact,
we present three distinct proteins: a cytosolic tryparedoxin
peroxidase of L. infantum (LicTXNPx) [61], the Leishma-
nia silent information regulator 2 (Sir2) [52], and a try-
paredoxin of L. infantum (LiTXN1) [62]. All are Leishma-
nia secreted proteins (Figure 1)[ 52], that show distinct im-
munological properties. A high antibody titre against the
LicTXNPx was detected in children [63]. This antibody titre
is maintained during the Leishmania infection and decreases
after its resolution [63]. Despite its high immunogenicity
when tested in vitro or in vivo using the Balb/c model, this
excreted/secreted protein did not show immunomodulatory
properties (Figures 4, 5,a n dTable 1) and provided no pro-
tection against the infectious challenge (data not shown).
On the other hand, the Leishmania Sir2 is a typical poorly
immunogenic secreted antigen (Figure 2) characterized as a
virulence factor [64]. Infectious challenge after Leishmania
Sir2 immunization results in a decreased infectivity in the
acute phase (Figure 3). This could be partially due to the
production of lytic and neutralizing antibodies [65]. The
immunization leads to a signiﬁcant decrease of the spleen4 Journal of Biomedicine and Biotechnology
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Weeks after L. infantum infection
Figure 2: Antibodies against Leishmania SIR2 protein in the sera of
chronicallyL.infantuminfectedBalb/cmice.Serafrom108 intraperi-
toneal (i.p.) L. infantum promastigotes infected Balb/c mice after 2,
8, 11, 15, 17, and 19 weeks, were used in a western blot against 1μg
of rLiSIR2 at two diﬀerent dilutions, 1 : 200 and 1 : 50 (left and
right lanes, respectively, for each diﬀerent serum). A 0 weeks serum
was obtained from noninfected mice.
and liver parasite load at two weeks post infection (Figure 3)
[65]. However, it is incapable by itself of resolving the in-
fection, as seen six weeks after infection, where there is no
signiﬁcant diﬀerence between the immunized infected group
and the infected control group (Figure 3). Certain secreted
proteins seem to function as immunomodulatory compo-
nents, acting as host immune evasive proteins. As an exam-
ple, another excreted/secreted Leishmania protein, LiTXN1
(Figure 1), is capable to increase IL-10 splenocyte secretion
(Table 1), a major immunosuppressive cytokine (manuscript
in preparation). LiTXN1 can be among the proteins respon-
sible for a transient immunosuppressive state that can favour
the parasite internalization and colonization of the host cells.
These examples show that among the secreted proteins we
can ﬁnd proteins naturally immunogenic, albeit nonprotec-
tive, like LicTXNPx while others less immunogenic show in-
teresting properties in terms of protection probably due to
the disruption of their in vivo functions, Leishmania Sir2, or
by their immunomodulatory properties, LiTXN1. Unfortu-
nately, the reduced immunogenicity of the most interesting
secretedproteinsprobablywillpreventtheiridentiﬁcationby
serological based approaches [51].
The reduction of the secreted/excreted proteins to the
given examples is an oversimpliﬁcation. However, it is ob-
vious that much more work is needed in this area, especially
in the huge black hole of knowledge that concerns the inter-
action between host cell and Leishmania at a molecular level.
Since most of the studies have been done using infection-
phenotype approaches, little is known about the true agents
involved in macrophagic disruption [16, 58, 68, 69]. We sug-
gest that amastigote secreted proteins will be more immuno-
genic and can have interesting immunomodulatory proper-
ties since they have not been under the selective pressure as
the promastigote secreted proteins. The selective pressure of
the host immune system is a powerful driving force in evolu-
tion,asdemonstratedinthecaseofSchistosomamansonithat
has the ability to completely evade the host immune system
rendering itself “invisible” [70].
1.3. Panantigens—nonsecretedproteins
Human visceral leishmaniasis, unlike cutaneous leishmani-
asis is characterized by high anti-Leishmania antibody titres
[71, 72]. The role of these antibodies is still unclear as there
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Figure 3: The recombinant Leishmania SIR2 immunization reduces
the parasite load in an acute phase of L. infantum Balb/c mice infec-
tion. The immunized mice () received 3 i.p. injections of recom-
binant Leishmania SIR2 (50μg) once a week and infected 2 weeks
after the last immunization with 108 L. infantum stationary phase
promastigotes. The nonimmunized mice () were subjected to the
same protocol but received PBS instead of recombinant Leishmania
SIR2. The mice were sacriﬁced after 2 and 6 weeks of infection and
the parasite load in the spleen and liver determined by the organ
limiting dilution method [66]. The data represent means and stan-
dard deviations for three mice and are representative of two inde-
pendent experiments. Statistical analysis was performed using Stu-
dent t-test. Statistically, signiﬁcant diﬀerences between immunized
and nonimmunized mice are indicated. ∗P<. 05.
seems to be no relation with the progression or resolution
of the infection[58, 73, 74]. This exuberant humoral re-
sponse against promastigote and amastigote antigens (frac-
tions or total protein extract or speciﬁc Leishmania proteins)
has been exploited for serodiagnosis with diﬀerent degrees
of success [58, 63, 74, 75]. Interestingly, one of the most
sensitive techniques using recombinant Leishmania proteins
does not involve surface molecules like LPG or gp63 butNuno Santar´ em et al. 5
Table 1: Immunomodulatory properties of several Leishmania proteins
Protein Properties References
Leishmania Sir2 Secreted, B-cell activator, induces lytic, and neutralizing antibodies [64, 65]
LicTXNPx Secreted, elicits strong humoral response and has no inﬂuence on
cytokine production [63]
LimTXNPx Nonsecreted, decreases IL-4 secretion both in vitro and in vivo Figure 3
LiTXN1 Secreted, poorly immunogenic, induces IL-10 secretion both in vitro
and in vivo
(Manuscript in
preparation)
LmS3arp Nonsecreted, B-cell polyclonal activator, inhibits T-cell proliferation,
and downregulate IL-2, 12 and IFN-γ in splenocytes [67]
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(a)
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Ctrl LimTXNPx Ctrl LimTXNPx
ConA
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Figure 4: No eﬀect of rLicTXNPx and rLimTXNPx (a) on spleen cell
proliferation. S p l e e nc e l l sf r o mn o r m a lB a l b / cm i c ew e r ec u l t u r e d
for 48 hours (2.5 × 105 cells/well) in the presence or absence of
concanavalin A (ConA) (5μg/ml) with or without rLicTXNPx and
rLimTXNPx(b)(10μg/ml).Thecellswerepulsedwith[methyl-3H]
thymidine in the last 8 hours of culture, and cpm (scintillations per
minute) were determined. The data represent mean cpm and stan-
dard deviations from triplicate cultures of spleen cells from three
mice analyzed individually. One of three independent experiments
is depicted.
intracellular proteins like histones [75]. The screening of
Leishmania expression libraries or total protein extract with
serum from infected patients has unveiled several major im-
munogens [76–79]. Among these immunogens, nonsecreted
proteins like heat shock proteins, ribosomal proteins and hi-
stones were described [76, 77, 80]. These highly-conserved
proteins that elicit strong immune responses are generally
designated as panantigens [81]. The elevated antibody titre
against conserved proteins can be the direct result of B-
lymphocytes polyclonal activation similar to what is found
in Chagas disease [82, 83] or in autoimmune diseases [84].
Furthermore, in the Balb/c mouse model, an L. major pro-
tein homologue to the mammalian ribosomal protein S3a,
LmS3arp, (Table 1) is able to elicit an unspeciﬁc activation
of B-lymphocytes with the production of autoreactive anti-
bodies [67]. Despite this, in natural infections, the humoral
and cellular responses are highly speciﬁc with no signiﬁcant
autoantibody production [80, 81, 85]. Moreover, the epi-
tope mapping of several Leishmania panantigens tends to re-
veal Leishmania unique epitopes that elicit strong immune
responses [79–81, 86, 87]. There is practically no response
to the homologous regions in these proteins, which argues
against the nonspeciﬁc polyclonal activation as the source
of reactivity against Leishmania panantigens [11, 81]. So, it
is expected that these proteins are presented to the immune
system during the natural course of the infection. Unlike se-
creted and surface proteins that are exposed and can be pro-
cessed by the host immune system, the intracellular proteins
are not. One must expect that the contact between the im-
mune system and these proteins happens only upon the par-
asite destruction. Subsequently, one obvious source of in-
tracellular proteins is the parasites from the initial inocu-
lum some of which are destroyed. Furthermore, it was re-
cently demonstrated that the presence of apoptotic parasites
in the initial inoculum is a requisite for disease development
[88]. Albeit the small number of parasites in the initial in-
oculum is not suﬃcient to explain the physical expansion of
cell populations and immune mediators during the course of
infection, it is a fact that panantigens are exposed long be-
fore the onset of any visible symptoms [88]. This initial re-
lease of panantigens may function in conjugation with the
secreted and surface proteins acting as a transient “smoke
screen” that enables the onset of the initial infection by vi-
able parasites. The immune response developed against the
panantigens may contribute to hide the parasite molecules6 Journal of Biomedicine and Biotechnology
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Figure 5: Levels of IL-4 in the supernatants of spleen cells from
rLicTXNPx or rLimTXNPx treated and untreated Balb/c mice. The
spleen cells from untreated (a) and treated (b) Balb/c mice (50μg
of rLicTXNPx or rLimTXNPx i.p. injected once a week for 3 weeks
followed by 2 weeks before the spleen cells were recovered) were in-
c u b a t e dwi t hr LicTXNPx or rLimTXNPx (10μg/ml) in the presence
or absence of ConA (5μg/ml) for 48 hours. The levels of IL-4 were
determined by ELISA in comparison with a standard curve using
the recombinant IL-4. The data represent means and standard de-
viations for triplicate cultures of spleen cells from three mice. The
results are from a representative experiment of three carried out
independently. Statistical analysis was performed using Student t-
test. Statistically, signiﬁcant diﬀerences is indicated. ∗P<. 05 and
∗∗P<. 01.
involved in the invasion of the phagocytic cells. Moreover,
the humoral proﬁle suggests a steady release of panantigens
during the infection [58, 73, 74]. It is also [81]s u g g e s t e d
that panantigens originate from the residing parasite pop-
ulation either by the destruction of intracellular amastig-
otes by active macrophages or by the destruction of amastig-
otes that burst from macrophages or even by the sponta-
neous cytolysis of amastigotes inside the infected cells [11].
In active leishmaniasis, there seems to be a general anergy
in infected macrophages that leads to impaired functioning
[16, 89–92]. So, in this case, it is not expected that pananti-
gens may result from the macrophage mediated elimination
of Leishmania, as it will lead to the resolution of the infec-
tion. Although free amastigotes can infect macrophages di-
rectly, they are almost undetectable even in heavily infected
hosts. Thus, their contribution to the pool of panantigens
should be diminished [11]. The low speed of intracellular
amastigotes multiplication and their capacity to delay apop-
tosis in heavily infected phagocytes [60] enables a lasting co-
existence in infected macrophages. The most viable theory
for the phased release of panantigens would be the sponta-
neous cytolysis (described as apoptosis by some authors) of
intracellular amastigotes [93]. The eﬀect of the panantigen
release is gradual and more signiﬁcant as the infection devel-
opsandtheparasiteburdenaugmentsexplainingtheincreas-
ing intense immunopathology associated with Leishmania
infection [11]. This increase in panantigen release can be ex-
trapolatedincorrelationwithpanantigenantibody titresand
parasite burden as seen for the Leishmania kinesin like pro-
tein,k39[81,94].Anotherproteinthatshowssimilarcharac-
teristics to k39 is the LicTXNPx which has also the ability to
induce a high quantity of nonprotective antibodies both in
natural or experimentally infected dogs (unpublished data)
and in infected humans [63]. This induction can be done
by direct activation on B-cell populations with clonal expan-
sion as described for Leishmania Sir2 [65], which seems not
to be the case since little or no antibodies for LicTXNPx are
seen in HIV patients with leishmaniasis (unpublished data),
as was observed for k39 [95]. This suggests the existence of
speciﬁc T-cell epitopes in LicTXNPx. The nature of these
epitopes will not be similar to those of k39, because the lat-
ter contain repetitive motifs that will contribute signiﬁcantly
to the clonal expansion of B-cells. For LicTXNPx, the strong
immune response observed should be due to the formation
of highly stable multimeric structures characteristic of this
protein [96]. The nonprotective antibody titres induced by
LicTXNPx seem to be transient and associated only with the
immunopathology as they disappear after a period of time,
unlike other Leishmania speciﬁc antibodies simultaneously
in circulation [63]. These antibodies may contribute to the
impairment of bone marrow and spleen [11].
The capacity of panantigens to modulate the immune
system can be related to the fact that these intracellular
proteins were not selected by the immune pressure, unlike
the secreted and surface proteins. Hence, in the right con-
ditions, they can provide the immunomodulatory proper-
ties needed for vaccine design. The most prominent intra-
cellular proteins used in vaccine design are still LACK and
LmSTI1 that are able to induce protective responses with
a parasite-speciﬁc Th1 immune response (high IFN-γ but
not IL-4 secretion) [87, 97]. Among the Leishmania pro-
teins studied by our group, a mitocondrial tryparedoxin per-
oxidase (LimTXNPx; Table 1), homologous to LicTXNPx,
is able to induce down regulation of IL-4, a Th2 cytokine,
in splenocytes both in vitro and in vivo (Figure 5) though
unable to induce signiﬁcant protection (data not shown).
It is noteworthy that similar proteins such as LicTXNPx
and LimTXNPx are able to elicit distinct immune responses.Nuno Santar´ em et al. 7
LicTXNPx is secreted inducing only the production of non-
protective antibodies, while its related intracellular counter-
part LimTXNPx has immunomodulatory properties inter-
fering with cytokine production (Figure 5). This can be a
good example of the type of evolutionary pressure induced
by the immune system, in which two related proteins have
distinctimmunomodulatoryproperties(Figures4,5).Itsug-
gests that the host immune system selects characteristics in
the exposed proteins that are either innocuous or nondelete-
rious to the parasite. Since this does not occur in the intra-
cellular proteins they can retain distinct immunoregulatory
properties that could be useful in vaccine design.
2. CONCLUDING REMARKS
Taken altogether, these observations support the idea that se-
creted and surface proteins tend to be poor or nonprotec-
tive immune modulators, like LicTXNPx. Nonetheless, their
use in vaccine could induce short-lived protection probably
due to the disruption of their biological activity or by pro-
duction of lytic antibodies, as seen with Leishmania Sir2. In-
tracellular components like LmS3arp and LimTXNPx tend
to have deﬁned immunomodulatory properties. LmS3arp is
able to induce polyclonal activation of B lymphocytes while
LiLimTXNPxTXNPx confers a nonprotective dowregulation
of IL-4 secretion by splenocytes.
Using the basic knowledge acquired in the study of the
immune response against Leishmania in diﬀerent murine
models, one can look for proteins that induce the immuno-
logical phenotype needed for protection. Therefore, our data
suggests that in vaccine development, the conjugation of se-
creted and surface proteins with intracellular components
should provide a more eﬃcient protection. Hence, the im-
pairment of the parasite entrance in the host cells, either
by lytic antibodies or by the disruption of protein function,
will delay the onset of the immune suppression associated
with Leishmania. The parasite elimination could be achieved
through a protective cellular response, induced by the intra-
cellular parasite components present in the vaccine.
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